West Pharmaceutical Services (WST) reported Q3 adjusted earnings Thursday of $1.85 per diluted share, down from $2.16 a year earlier.
Analysts polled by Capital IQ expected $1.49.
Revenue for the quarter ended Sept. 30 was $746.9 million, compared with $747.4 million a year earlier.
Analysts surveyed by Capital IQ expected $709.6 million.
The company increased its 2024 adjusted EPS guidance to now be between $6.55 and $6.75 from the prior outlook of $6.35 to $6.65. Analysts polled by Capital IQ expect $6.41.
Net sales for the year are projected to be about $2.88 billion to about $2.91 billion, compared with a prior range of $2.87 billion to $2.90 billion. Analysts surveyed by Capital IQ expect $2.87 billion.
Price: 306.21, Change: +19.77, Percent Change: +6.90
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。